‘GlaxoSmithKline sought to reassure investors yesterday by announcing it would file its potential blockbuster cervical cancer vaccine, Cervarix, for approval in the US before the end of the year.

The news came after the British pharmaceuticals giant unveiled its best annual performance since 2000 when it was formed from the merger of SmithKline Beecham and Glaxo Wellcome. Strong sales of the asthma drug Advair propelled sales to £21.7bn last year, up 8 per cent. With pre-tax profits rising to £6.7bn, earnings per share were up 21 per cent to 82.6p, better than City expectations.’

Read more at GlaxoSmithKline unveils best results since merger

Recent Entries

• Sigma Pharmaceuticals year profit rises 27 pct
• South African citizens cheap drug guinea pigs
• Two drugs test victims face a year in coma
• Can drug companies improve their reputation?
• Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
• Pfizer’s Forecast Disappoints
• Pharmaceutical RFID Adoption Stalls
• Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
• GlaxoSmithKline unveils best results since merger
• Pfizer Sues Teva, Sandoz Over Zithromax

This entry was posted on Thursday, February 9th, 2006 at 10:22 pm and is filed under General. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.